Transplantation Direct最新文献

{"title":"Video-assisted Retroperitoneal Debridement for Graft Pancreatitis.","authors":"Brian I Shaw, Michela M Fabricius, Christopher L Nauser, Sabino Zani, Stuart J Knechtle","doi":"10.1097/TXD.0000000000001682","DOIUrl":"10.1097/TXD.0000000000001682","url":null,"abstract":"","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"10 8","pages":"e1682"},"PeriodicalIF":1.9,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11286245/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141793487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding the Donor Pool to the Ultimate Level: Introducing the Revolutionary Hybrid Dual Graft Liver Transplant Using Domino and Living Donors.","authors":"Ahmed Zidan, Hammam Momani, Bodhisatwa Sengupta, Rehab Abdullah, Razan Bader, Iftikhar Khan, Mansour Tawfeeq, Mohammed Al Qahtani","doi":"10.1097/TXD.0000000000001681","DOIUrl":"10.1097/TXD.0000000000001681","url":null,"abstract":"<p><strong>Background: </strong>Innovative solutions are crucial as the demand for liver transplants continues to outpace available grafts. Dual graft liver transplantation offers a promising avenue to address graft volume challenges while minimizing donor risks. This report introduces a groundbreaking approach, combining a full organ domino donor graft with a living donor graft for a hybrid dual graft liver transplant.</p><p><strong>Brief report: </strong>A 2-y-old child with Maple syrup urine disease and a 40-y-old adult with end-stage liver disease became the focus of this unique case. A hybrid dual graft liver transplant was executed, uniting the domino donor's full organ graft with a living donor's left lateral segment. Precise vascular and biliary reconstructions facilitated a successful transplant.</p><p><strong>Conclusions: </strong>The hybrid dual graft liver transplant, merging domino donor and living donor grafts, presents a viable strategy to combat graft shortages, particularly in regions predominantly reliant on living donor transplants. Despite challenges, this pioneering approach should be embraced by established liver transplant centers because it enables concurrent living donor liver transplantation while prioritizing donor safety and recipient outcomes.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"10 8","pages":"e1681"},"PeriodicalIF":1.9,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11286240/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141793484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rapid Development of Post-Liver Transplantation Nodular Regenerative Hyperplasia and Portal Hypertension After Perfusion Pump Use: A Case Series.","authors":"Sachiko M Oshima, Wei Chen, Aparna Rege, Andrew S Barbas, Stephanie Garbarino","doi":"10.1097/TXD.0000000000001688","DOIUrl":"10.1097/TXD.0000000000001688","url":null,"abstract":"","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"10 8","pages":"e1688"},"PeriodicalIF":1.9,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11286241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141793485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Cost-effectiveness of Valganciclovir Prophylaxis Versus Preemptive Therapy in CMV R+ Kidney Transplant Recipients Over the First Year Posttransplantation.","authors":"Claire Villeneuve, Jean-Phillipe Rerolle, Lionel Couzi, Pierre-Francois Westeel, Isabelle Etienne, Laure Esposito, Nassim Kamar, Mathias Büchler, Antoine Thierry, Pierre Marquet, Caroline Monchaud","doi":"10.1097/TXD.0000000000001678","DOIUrl":"10.1097/TXD.0000000000001678","url":null,"abstract":"<p><strong>Background: </strong>In kidney transplant recipients with positive serology (R+) for the cytomegalovirus (CMV), 2 strategies are used to prevent infection, whose respective advantages over the other are still debated. This study aimed to evaluate the cost-effectiveness and cost utility of antiviral prophylaxis against CMV versus preemptive therapy, considering CMV infection-free survival over the first year posttransplantation as the main clinical outcome.</p><p><strong>Methods: </strong>Clinical, laboratory, and economic data were collected from 186 kidney transplant patients CMV (R+) included in the cohort study (85 patients who benefited from CMV prophylaxis and 101 from preemptive therapy). Costs were calculated from the hospital perspective and quality-adjusted life years (QALYs) using the EQ5D form. Using nonparametric bootstrapping, the incremental cost-effectiveness ratio (ICER) and cost utility were estimated (euros) for each case of infection avoided and each QALY gained for 1 y, respectively.</p><p><strong>Results: </strong>Prophylaxis significantly decreased the risk of CMV infection over the first year posttransplantation (hazard ratio 0.22, 95% confidence interval = 0.12-0.37, <i>P</i> < 0.01). Compared with preemptive therapy, prophylaxis saved financial resources (€1155 per patient) and was more effective (0.42 infection avoided per patient), resulting in an ICER = €2769 per infection avoided. Prophylaxis resulted in a net gain of 0.046 in QALYs per patient and dominated over preemptive therapy with €1422 cost-saving for 1 QALY gained.</p><p><strong>Conclusions: </strong>This study shows that CMV prophylaxis, although considered as a more expensive strategy, is more cost-effective than preemptive therapy for the prevention of CMV infections in renal transplant patients. Prophylaxis had a positive effect on quality of life at reasonable costs and resulted in net savings for the hospital.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"10 8","pages":"e1678"},"PeriodicalIF":1.9,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11286253/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141793486","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International Travel for Organ Transplantation: Provider and Patient Perspectives.","authors":"Ann B Nguyen, Hannah F Roth, Bow Chung, Daniel Rodgers, Kevin J Clerkin, Gabriel Sayer, Gene Kim, Valluvan Jeevanandam, Mark Siegler, Nir Uriel, Andrew Aronsohn","doi":"10.1097/TXD.0000000000001686","DOIUrl":"10.1097/TXD.0000000000001686","url":null,"abstract":"<p><strong>Background: </strong>Organ allocation in the United States to non-US citizen, non-US residents who travel for transplant (NC/NRTx) is controversial. Current policies may not be informed by stakeholder opinions, as limited data exist assessing the knowledge or opinions of providers or patients on this issue.</p><p><strong>Methods: </strong>A cross-sectional, hospital-based pilot survey was distributed to providers and patients from December 2019 to June 2020 at a single large urban transplant institute. Providers were members of the departments of surgery and medicine and included both transplant and nontransplant providers. Surveys included 10 questions on eligibility, prioritization, and limitations for deceased donor transplantation and 12 demographic questions.</p><p><strong>Results: </strong>A total of 209 providers responded (61% women, median age 40) and 119 patients responded (62% women, median age 54). Awareness of eligibility for transplantation of US citizens, non-US citizens residing in the United States (NC/R), and NC/NRTx was high in both groups, though providers and patients lacked awareness of the eligibility of nonlegal NC/R (those who live in the United States who are not citizens and are not legal residents) to donate and receive organs. Overall, 79.3% of patients stated that NC/NRTx should be eligible for transplant in the United States compared with only 60.7% of providers (<i>P</i> = 0.001). Providers were more likely than patients to prioritize transplant to legal NC/NR over NC/NRTx (58.2% versus 35.1%, <i>P</i> < 000.1) and reported that families should be able to limit donations to NC/NRTx (34.9% versus 23.2%, <i>P</i> = 0.03).</p><p><strong>Conclusions: </strong>Surveyed patients and providers generally support transplant in non-US citizens; however, the strength of support varied considerably based on the legal status of the patient and the occupation of those surveyed. Larger studies are necessary to develop data-informed policy.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"10 8","pages":"e1686"},"PeriodicalIF":1.9,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11259398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141735066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of COVID-19 Hospitalization and Death Between Solid Organ Transplant Recipients and the General Population in Canada, 2020-2022.","authors":"Kyla L Naylor, Gregory A Knoll, Darin Treleaven, Yuguang Kang, Amit X Garg, Kathryn Stirling, S Joseph Kim","doi":"10.1097/TXD.0000000000001670","DOIUrl":"10.1097/TXD.0000000000001670","url":null,"abstract":"<p><strong>Background: </strong>Solid organ transplant recipients have a high risk of severe outcomes from SARS-CoV-2 infection. A comprehensive understanding of the impact of the COVID-19 pandemic across multiple waves in the solid organ transplant population and how this compares to the general population is limited. We conducted a population-based cohort study using linked administrative healthcare databases from Ontario, Canada to answer this question.</p><p><strong>Methods: </strong>We included 15 306 solid organ transplant recipients and 12 160 904 individuals from the general population. Our primary outcome was the rate (per 100 person-years) of severe COVID-19 (ie, hospitalization or death with a positive SARS-CoV-2 test) occurring between January 25, 2020, and November 30, 2022.</p><p><strong>Results: </strong>Compared with the general population, solid organ transplant recipients had almost a 6 times higher rate of severe COVID-19 (20.39 versus 3.44 per 100 person-years), with almost 5.5 times as high a rate of death alone (4.19 versus 0.77 per 100 person-years). Transplant recipients with severe COVID-19 were substantially younger (60.1 versus 66.5 y) and had more comorbidities. The rate of severe COVID-19 declined over time in the solid organ transplant population, with an incidence rate of 41.25 per 100 person-years in the first wave (January 25, 2020, to August 31, 2020) and 18.41 in the seventh wave (June 19, 2022, to November 30, 2022, Omicron era).</p><p><strong>Conclusions: </strong>Solid organ transplant recipients remain at high risk of severe outcomes when they are infected with SARS-CoV-2. Resources and strategies to mitigate the impact of SARS-CoV-2 exposure are needed in this vulnerable patient population.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"10 7","pages":"e1670"},"PeriodicalIF":1.9,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216672/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized Controlled Trial of Enhanced Recovery After Surgery Protocols in Live Kidney Donors: ERASKT Study.","authors":"Jacob Saks, Uzung Yoon, Natalie Neiswinter, Eric S Schwenk, Stephen Goldberg, Linh Nguyen, Marc C Torjman, Elia Elia, Ashesh Shah","doi":"10.1097/TXD.0000000000001663","DOIUrl":"10.1097/TXD.0000000000001663","url":null,"abstract":"<p><strong>Background: </strong>Enhanced recovery after surgery (ERAS) pathways represent a comprehensive approach to optimizing perioperative management and reducing hospital stay and cost. In living donor kidney transplantation, key impediments to postoperative discharge include pain, and opioid associated complications such as nausea, vomiting, and the return of gastrointestinal function.</p><p><strong>Methods: </strong>In this randomized controlled trial, living kidney transplantation donors were assigned to either the ERAS or control group. The ERAS group patients received 15 preoperative, 17 intraoperative, 19 postoperative element intervention. The control group received standard care. The ERAS group received a multimodal opioid sparing pain management including an intraoperative transverse abdominis plane block. Our primary outcome measure was postoperative opioid consumption. The secondary outcome measures were postoperative pain scores, first oral intake, and hospital length of stay.</p><p><strong>Results: </strong>There were no significant differences in demographics between the 2 groups. The ERAS group had a statistically significant reduction in total postoperative opioid consumption calculated in intravenous morphine equivalents (24.2 ± 20.2 versus 71 ± 39.5 mg, <i>P</i> < 0.01). Postoperative pain scores were significantly lower (<i>P</i> < 0.001) from 1 h postoperatively to 48 h. Surgical time was 45 min shorter (<i>P</i> = 0.037). Intraoperative PlasmaLyte administration was lower (PlasmaLyte: 1444 ± 907 versus 2168 ± 1347 mL, <i>P</i> = 0.049). Time to tolerating regular diet was shorter by 2 h (<i>P</i> < 0.008), and length of hospital stay was decreased by 10.1 h.</p><p><strong>Conclusions: </strong>The ERAS group experienced superior postoperative analgesia and a shorter length of hospital stay compared with controls.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"10 7","pages":"e1663"},"PeriodicalIF":1.9,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Risk of Microbial Transmission in Recipients of Donor Livers That Underwent Hypothermic or Normothermic Machine Perfusion.","authors":"Chikako Endo, Bianca Lascaris, Isabel M A Brüggenwirth, Jan Roggeveld, Hans Blokzijl, Vincent E de Meijer, M H Edwina Doting, Robert J Porte","doi":"10.1097/TXD.0000000000001664","DOIUrl":"10.1097/TXD.0000000000001664","url":null,"abstract":"<p><strong>Background: </strong>Ex situ machine perfusion is increasingly used to preserve and assess donor livers before transplantation. Compared with traditional static cold storage (SCS), machine perfusion exposes livers to an additional risk of microbial contamination. However, information on the risk of microbial transmission during machine perfusion is lacking.</p><p><strong>Methods: </strong>All livers that underwent either hypothermic oxygenated machine perfusion (HOPE) or normothermic machine perfusion (NMP) in our center between September 2021 and September 2023, and during which samples were taken from SCS fluid and/or machine perfusion solution for microbiological examination, were included in this retrospective, observational clinical study. Microbial transmission was examined from SCS fluid to machine perfusion solution fluid and, subsequently, to recipients of these livers.</p><p><strong>Results: </strong>A total of 90 cases of liver machine perfusion were included: 59 HOPE and 31 NMP. SCS preservation fluid cultures before HOPE or NMP were positive for at least 1 microorganism in 52% of the cases. After HOPE, there were no cases of positive machine perfusion fluid or evidence of microbial transmission to the recipients. After NMP, in 1 (3%) patient <i>Escherichia coli</i> was grown from abdominal drain fluid, the same bacterial strain that was also grown from the SCS preservation fluid before NMP. This <i>E coli</i> was resistant to the antibiotics that are routinely added to the NMP perfusion fluid.</p><p><strong>Conclusions: </strong>The risk of microbial transmission after machine perfusion is very low but not absent. We recommend routine sampling of machine perfusion fluid at the end of the procedure for microbiological analysis.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"10 7","pages":"e1664"},"PeriodicalIF":1.9,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216676/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline Lung Allograft Dysfunction After Bilateral Lung Transplantation Is Associated With an Increased Risk of Death: Results From a Multicenter Cohort Study.","authors":"Michael B Keller, Junfeng Sun, Muhtadi Alnababteh, Lucia Ponor, Pali D Shah, Joby Mathew, Hyesik Kong, Ananth Charya, Helen Luikart, Shambhu Aryal, Steven D Nathan, Jonathan B Orens, Kiran K Khush, Moon Kyoo Jang, Sean Agbor-Enoh","doi":"10.1097/TXD.0000000000001669","DOIUrl":"10.1097/TXD.0000000000001669","url":null,"abstract":"<p><strong>Background: </strong>A prior single-center, retrospective cohort study identified baseline lung allograft dysfunction (BLAD) as a risk factor for death in bilateral lung transplant recipients. In this multicenter prospective cohort study, we test the association of BLAD with death in bilateral lung transplant recipients, identify clinical risk factors for BLAD, and assess its association with allograft injury on the molecular level.</p><p><strong>Methods: </strong>This multicenter, prospective cohort study included 173 bilateral lung transplant recipients that underwent serial pulmonary function testing and plasma collection for donor-derived cell-free DNA at prespecified time points. BLAD was defined as failure to achieve ≥80% predicted for both forced expiratory volume in 1 s and forced vital capacity after lung transplant, on 2 consecutive measurements at least 3 mo apart.</p><p><strong>Results: </strong>BLAD was associated with increased risk of death (hazard ratio, 1.97; 95% confidence interval [CI], 1.05-3.69; <i>P</i> = 0.03) but not chronic lung allograft dysfunction alone (hazard ratio, 1.60; 95% CI, 0.87-2.95; <i>P</i> = 0.13). Recipient obesity (odds ratio, 1.69; 95% CI, 1.15-2.80; <i>P</i> = 0.04) and donor age (odds ratio, 1.03; 95% CI, 1.02-1.05; <i>P</i> = 0.004) increased the risk of developing BLAD. Patients with BLAD did not demonstrate higher log₁₀(donor-derived cell-free DNA) levels compared with no BLAD (slope [SE]: -0.0095 [0.0007] versus -0.0109 [0.0007]; <i>P</i> = 0.15).</p><p><strong>Conclusions: </strong>BLAD is associated with an increased risk of death following lung transplantation, representing an important posttransplant outcome with valuable prognostic significance; however, early allograft specific injury on the molecular level does not increase the risk of BLAD, supporting further mechanistic insight into disease pathophysiology.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"10 7","pages":"e1669"},"PeriodicalIF":1.9,"publicationDate":"2024-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216668/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141477527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-based Disparities in Liver Transplantation for Hepatocellular Carcinoma and the Impact of the Growing Burden of NASH.","authors":"Jia Hong Koh, Douglas Chee, Cheng Han Ng, Karn Wijarnpreecha, Mark Muthiah, Darren Jun Hao Tan, Wen Hui Lim, Rebecca Wenling Zeng, Benjamin Koh, Eunice Tan Xiang Xuan, Glenn Bonney, Shridhar Iyer, Dan Yock Young, Toru Nakamura, Hirokazu Takahashi, Mazen Noureddin, Mohammad Shadab Siddiqui, Tracey G Simon, Rohit Loomba, Daniel Q Huang","doi":"10.1097/TXD.0000000000001642","DOIUrl":"10.1097/TXD.0000000000001642","url":null,"abstract":"<p><strong>Background: </strong>The cause of liver disease is changing, but its impact on liver transplantation (LT) for hepatocellular carcinoma (HCC) in women and men is unclear. We performed a nationwide study to assess the prevalence and posttransplant survival outcomes of the various causes of liver disease in women and men with HCC.</p><p><strong>Methods: </strong>Data were obtained from the United Network for Organ Sharing database from 2000 to 2022. Data related to the listing, transplant, waitlist mortality, and posttransplant mortality for HCC were extracted. The proportion of HCC related to the various causes of liver disease among LT candidates and recipients and posttransplant survival were compared between women and men.</p><p><strong>Results: </strong>A total of 51 721 individuals (39 465 men, 12 256 women) with HCC were included. From 2000 to 2022, nonalcoholic steatohepatitis (NASH) was the fastest-growing cause of liver disease among female LT candidates with HCC (<i>P</i> < 0.01), followed by alcohol-associated liver disease. NASH overtook chronic hepatitis C as the leading cause of liver disease in 2020 and 2022 among waitlisted women and men with HCC, respectively. Female patients with HCC spent a significantly longer time on the LT waitlist compared with male patients (β: 8.73; 95% confidence interval [CI], 2.91-14.54). Female patients with HCC from alcohol-associated liver disease also have a lower probability of receiving LT (subdistribution hazard ratio: 0.90; 95% CI, 0.82-0.99). Among transplant recipients with NASH HCC, female sex was associated with lower posttransplant mortality compared with male sex (hazard ratio: 0.79; 95% CI, 0.70-0.89; <i>P</i> < 0.01).</p><p><strong>Conclusions: </strong>Women have a significantly longer waitlist duration compared with men. NASH is now the leading cause of liver disease among both female and male LT candidates and recipients with HCC.</p>","PeriodicalId":23225,"journal":{"name":"Transplantation Direct","volume":"10 7","pages":"e1642"},"PeriodicalIF":1.9,"publicationDate":"2024-06-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11191941/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141443367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}